Clinical trial
Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults…
NCT00487942 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00487942 |
|---|---|
| Title | Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits |
| Official title | A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | armodafinil, placebo |
| Enrollment | 60 |
| Start date | Jul 1, 2007 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Jun 19, 2007 |
| Last update posted | Jul 19, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: